Pfizer logo is seen on Pfizer World Headquarters in Manhattan, New York, United States of America, ... [+] on July 6th, 2024. (Photo by Beata Zawrzel/NurPhoto via Getty Images)NurPhoto via Getty ImagesPfizer (NYSE: PFE) is scheduled to report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $12.95 billion and earnings of $0.44 on a per share and adjusted basis, lower than the consensus estimates. The company is likely to see higher sales, led by an uptick in Eliquis and Prev ...

Wall Street analysts expect Pfizer (PFE) to post quarterly earnings of $0.45 per share in its upcoming report, which indicates a year-over-year decline of 32.8%. Revenues are expected to be $13.13 billion, up 3.1% from the year-ago quarter.The current level reflects an upward revision of 0.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Before a company revea ...

Sangamo Therapeutics Inc SGMO, which developed a treatment in collaboration with Pfizer Inc PFE, received a boost to its stock price after struggling with liquidity issues.At last check Wednesday, Sangamo was up more than 36.2%, trading at 55 cents per share.Both companies released results from the Phase 3 AFFINE study of giroctocogene fitelparvovec, an investigational gene therapy for adult patients with moderately severe to severe hemophilia A.The AFFINE study achieved its primary objective.Also Read: Sec ...

Pfizer (PFE) will report its second-quarter 2024 earnings on Jul 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.22 billion and 45 cents per share, respectively. Earnings estimates for Pfizer have risen from $2.38 to $2.39 per share over the past seven days. For 2025, earnings estimates have been stable at $2.75 per share over the same timeframe.Image Source: Zacks Investment ResearchEarnings Surprise HistoryThe healthcare bellwether’s performance has been solid, ...

With danuglipron, Pfizer could become a major player in the massive GLP-1 agonist market.If there's one thing healthcare giant Pfizer (PFE -0.12%) really needs right now, it's a compelling growth catalyst. This year, the company isn't expecting much in the way of growth and investors are unsure about how strong its long-term prospects are, which explains why the stock is in such a slump -- down more than 25% in three years.But sometimes all it takes is one successful product to turn a company's fortunes aro ...

Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval.The treatment for hemophilia A could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for a less common type of the bleeding disorder called hemophilia B. Pfizer is co-developing the therapy with Sangamo Therapeutics, whose shares rose more than 60% on Wednesday following the ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Pfizer (PFE) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 30. On the other ...

Neither is a leader right now, but one of them might be on track to change that.Both Pfizer (PFE 0.88%) and Roche Holdings (RHHBY -0.18%) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes of Novo Nordisk and Eli Lilly.Still, both have ongoing plans to develop weight loss pills. If those plans pan out, the returns are likely to be enormous. So which of these dark ...

The pharma's latest push to develop a weight loss pill isn't going well.On July 11, Pfizer (PFE 0.88%) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the move could make it a direct competitor to the weight loss market's tycoons, Novo Nordisk and Eli Lilly.Alas, shareholders are more likely to be left wanting than they are to experien ...

Loading...Loading...Pfizer Inc PFE, one of the world’s largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.Currently, PFE stock is trading at around $30, showing a year-to-date gain of 2.6%, despite being down 16% over the past year.Chart created using Benzinga ProThe golden cross, where the short-term moving average crosses above the long-term moving average, is viewed by traders as a bullish signal.Ch ...